Cargando…
The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation
PURPOSE: Breast cancer in women is the most commonly diagnosed cancer. Adjuvant endocrine therapy (AET) showed consistent improvements in recurrence and survival rates. Adherence to adjuvant endocrine therapy remains essential for improving overall survival in women with hormone receptor (HR) positi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915802/ https://www.ncbi.nlm.nih.gov/pubmed/36778385 http://dx.doi.org/10.21203/rs.3.rs-2497342/v1 |
_version_ | 1784885975032266752 |
---|---|
author | Gomaa, Sameh Lopez, AnaMaria Slamon, Rachel Smith, Rita Telushi, Elma Lapitan, Emmanuel Nightingale, Ginah Miller, Suzanne Wen, Kuang-Yi |
author_facet | Gomaa, Sameh Lopez, AnaMaria Slamon, Rachel Smith, Rita Telushi, Elma Lapitan, Emmanuel Nightingale, Ginah Miller, Suzanne Wen, Kuang-Yi |
author_sort | Gomaa, Sameh |
collection | PubMed |
description | PURPOSE: Breast cancer in women is the most commonly diagnosed cancer. Adjuvant endocrine therapy (AET) showed consistent improvements in recurrence and survival rates. Adherence to adjuvant endocrine therapy remains essential for improving overall survival in women with hormone receptor (HR) positive breast cancer. However, early discontinuation of medicine is reported to range from 20% to 50%. Poor adherence has been attributed to multiple factors including presence of adverse events. We aim to report the lived experience of breast cancer survivors specifically as regards to side effects, the most reported reason for lack of adherence. METHODS: 35 breast cancer survivors on AET were interviewed. Qualitative iterative analysis was conducted using the grounded theory approach with the goal of identifying themes that emerge from the interviews and refining the question probes as needed. A codebook was developed and supplemented with interpretive codes generated through ongoing analysis of transcripts. All transcripts were coded using NVIVO qualitative data analysis software for data interpretations. RESULTS: Reported side effects associated with AET medications include hot flashes, sexual side-effects, joint pain, stiffness, cognitive function, mood changes, bone mass density decrease and fertility concerns. Women who were on AET more than 6 months reported more side effect concerns. A variety of coping strategies using over the counter medications or alternative medicines and approaches were also discussed. CONCLUSION: Tailored and timely information on potential AET-induced side effects and strategies to manage them is needed. In particular, some side effects are more prevalent by medication (e.g., joint pain in those who were taking an aromatases inhibitor). Provision of information to prepare women for the potential side effects of type of AET they are prescribed for would be helpful. IMPLICATIONS FOR CANCER SURVIVORS: As AET has been suggested for 10 years to improve surveillance and reduce recurrence, our results have implications for cancer survivors, especially the onsets of side effects and potential ways to manage them as they arise. |
format | Online Article Text |
id | pubmed-9915802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Journal Experts |
record_format | MEDLINE/PubMed |
spelling | pubmed-99158022023-02-11 The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation Gomaa, Sameh Lopez, AnaMaria Slamon, Rachel Smith, Rita Telushi, Elma Lapitan, Emmanuel Nightingale, Ginah Miller, Suzanne Wen, Kuang-Yi Res Sq Article PURPOSE: Breast cancer in women is the most commonly diagnosed cancer. Adjuvant endocrine therapy (AET) showed consistent improvements in recurrence and survival rates. Adherence to adjuvant endocrine therapy remains essential for improving overall survival in women with hormone receptor (HR) positive breast cancer. However, early discontinuation of medicine is reported to range from 20% to 50%. Poor adherence has been attributed to multiple factors including presence of adverse events. We aim to report the lived experience of breast cancer survivors specifically as regards to side effects, the most reported reason for lack of adherence. METHODS: 35 breast cancer survivors on AET were interviewed. Qualitative iterative analysis was conducted using the grounded theory approach with the goal of identifying themes that emerge from the interviews and refining the question probes as needed. A codebook was developed and supplemented with interpretive codes generated through ongoing analysis of transcripts. All transcripts were coded using NVIVO qualitative data analysis software for data interpretations. RESULTS: Reported side effects associated with AET medications include hot flashes, sexual side-effects, joint pain, stiffness, cognitive function, mood changes, bone mass density decrease and fertility concerns. Women who were on AET more than 6 months reported more side effect concerns. A variety of coping strategies using over the counter medications or alternative medicines and approaches were also discussed. CONCLUSION: Tailored and timely information on potential AET-induced side effects and strategies to manage them is needed. In particular, some side effects are more prevalent by medication (e.g., joint pain in those who were taking an aromatases inhibitor). Provision of information to prepare women for the potential side effects of type of AET they are prescribed for would be helpful. IMPLICATIONS FOR CANCER SURVIVORS: As AET has been suggested for 10 years to improve surveillance and reduce recurrence, our results have implications for cancer survivors, especially the onsets of side effects and potential ways to manage them as they arise. American Journal Experts 2023-01-30 /pmc/articles/PMC9915802/ /pubmed/36778385 http://dx.doi.org/10.21203/rs.3.rs-2497342/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. https://creativecommons.org/licenses/by/4.0/License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Article Gomaa, Sameh Lopez, AnaMaria Slamon, Rachel Smith, Rita Telushi, Elma Lapitan, Emmanuel Nightingale, Ginah Miller, Suzanne Wen, Kuang-Yi The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation |
title | The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation |
title_full | The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation |
title_fullStr | The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation |
title_full_unstemmed | The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation |
title_short | The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation |
title_sort | lived experience of breast cancer patients on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915802/ https://www.ncbi.nlm.nih.gov/pubmed/36778385 http://dx.doi.org/10.21203/rs.3.rs-2497342/v1 |
work_keys_str_mv | AT gomaasameh thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT lopezanamaria thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT slamonrachel thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT smithrita thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT telushielma thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT lapitanemmanuel thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT nightingaleginah thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT millersuzanne thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT wenkuangyi thelivedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT gomaasameh livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT lopezanamaria livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT slamonrachel livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT smithrita livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT telushielma livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT lapitanemmanuel livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT nightingaleginah livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT millersuzanne livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation AT wenkuangyi livedexperienceofbreastcancerpatientsonadjuvantendocrinetherapysideeffectsandcopingstrategiesduringthefirstyearofmedicationinitiation |